What is Amgens drug MariTide?
Obesity is a global health crisis that continues to plague populations worldwide, with staggering statistics indicating that over 70% of adults in the United States are either overweight or obese. Despite the scale of this epidemic, effective treatment options have been limited, leaving millions struggling to manage their weight and associated health complications. However, the tide may be turning as Amgen, a leading biotech company, presents a promising new candidate in the fight against obesity – MariTide, also known as maridebart cafraglutide.
MariTide is a first-of-its-kind bispecific molecule that harnesses the power of two key metabolic pathways to drive significant weight loss. By simultaneously activating the glucagon-like peptide-1 (GLP-1) receptor and antagonizing the glucose-dependent insulinotropic polypeptide (GIPR), MariTide aims to revolutionize the treatment of obesity.
Let’s delve into the science behind MariTide, explore the promising results from Amgen’s clinical trials, and uncover the potential implications of this groundbreaking therapy for millions of individuals grappling with the challenges of obesity.
Understanding the obesity epidemic
Obesity is a complex condition that has reached pandemic proportions globally. According to the World Health Organization (WHO), the worldwide prevalence of obesity has tripled over the past four decades, with nearly 40% of adults classed as overweight and 13% considered obese.
The consequences of this epidemic are far-reaching, with obesity linked to a host of serious medical complications, including type 2 diabetes, cardiovascular disease, certain types of cancer, and even mental health issues. The burden on healthcare systems worldwide is staggering, with estimates suggesting that obesity-related costs account for up to 3% of a country’s total healthcare expenditure.
Despite the widespread recognition of obesity as a chronic disease, the development of effective treatment options has been challenging. Traditional approaches, such as lifestyle modifications and bariatric surgery have had limited success, with the vast majority of individuals struggling to achieve and maintain significant weight loss.
Introducing MariTide: A novel bispecific molecule
Amgen’s drug MariTide represents a groundbreaking approach to obesity treatment, harnessing the power of two key metabolic pathways to drive weight loss. The molecule is designed to simultaneously activate the GLP-1 receptor and antagonize the GIPR, a unique combination that has shown promise in preclinical and early-stage clinical studies.
GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and appetite. By activating the GLP-1 receptor, MariTide can enhance insulin secretion, slow gastric emptying, and promote feelings of fullness, leading to reduced calorie intake and subsequent weight loss. On the other hand, GIPR antagonism has been identified as a complementary strategy, as it can further enhance the weight-lowering effects by reducing the body’s ability to store excess calories as fat.
The dual action of these two mechanisms is what sets MariTide apart from other obesity treatments currently on the market or in development. By targeting these pathways simultaneously, the molecule aims to deliver a more potent and durable weight loss response, potentially offering a more effective solution for individuals struggling with obesity.
Amgen’s clinical trial findings
Amgen has carried out research to evaluate the safety and efficacy of MariTide, with promising results emerging from their Phase 1 clinical trials. The study published in the journal, Nature Metabolism, enrolled individuals with obesity, but without diabetes and showed significant weight loss outcomes with MariTide.
In the multiple ascending doses (MAD) groups, participants taking MariTide experienced mean per cent changes in body weight ranging from 7.2% at the lowest dose (140 mg administered every four weeks) to 14.5% at the highest dose (420 mg every four weeks), by day 85 of the study. Importantly, the weight loss observed was maintained well beyond the treatment period, highlighting the potential for long-term effects.
The safety profile of MariTide was also encouraging, with the majority of side effects being mild and short lived. The most common were gastrointestinal-related, such as nausea and vomiting, which typically resolved within 48 hours.
These promising Phase 1 results paved the way for Amgen to initiate a Phase 2 dose-ranging study in early 2023, with the results expected in late 2024.
The potential impact of MariTide
The successful development and approval of MariTide could have a great impact on the weight loss drug market.
One of the key advantages of MariTide lies in its dual mechanism of action. By simultaneously targeting the GLP-1 and GIPR pathways, this therapy has the potential to address the complex nature of obesity. This approach could lead to more substantial and sustainable weight loss results, potentially improving overall health and quality of life for individuals struggling with obesity.
A favorable safety profile observed in the Phase 1 trials suggests that MariTide may offer a well-tolerated treatment option, which could enhance patient compliance and long-term success. The ability to maintain weight loss beyond the treatment period is also a significant advantage, as it could help individuals achieve lasting results and reduce the risk of weight regain, a common challenge with many obesity drugs.
If approved, MariTide could potentially expand the treatment landscape for obesity, providing a much-needed alternative for the millions of individuals who have been unable to achieve their weight loss through traditional methods.
The obesity treatment landscape
MariTide is welcomed by healthcare providers and patients alike who continue to struggle with the limitations of existing therapies.
Traditional approaches, such as lifestyle changes and bariatric surgery often fail in delivering sustained weight loss. Pharmacological interventions, while offering more targeted solutions, have historically been let down by modest efficacy, safety concerns, or limited long-term results.
The discovery of GLP-1 receptor agonists, such as Novo Nordisk’s Wegovy (semaglutide) has been a significant improvement in the field, showing the potential of targeting the GLP-1 pathway to increase weight loss. Eli Lilly’s Zepbound (tirzepatide) injection combines the effects of two hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), to regulate blood sugar levels and promote weight loss. However, even these therapies have room for improvement, as some individuals may not achieve their desired weight loss goals, or may experience challenges with long-term maintenance.
Conclusion
MariTide’s unique dual approach, targeting both the GLP-1 and GIPR pathways, has the potential to address limitations and provide a better solution for obesity management. By using the synergistic effects of these two key metabolic pathways, the therapy aims to deliver more potent and sustained weight loss results for individuals struggling with this chronic condition.
Sources
Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
Related Articles
Trusted and certified to keep your data safe.
WHY WE BUILT NOWPATIENT
We are committed to helping everyone, everywhere live healthier lives
The NowPatient virtual care platform provides you with access to trusted health information, affordable treatments, management of chronic health conditions and continuous monitoring for health risks. NowPatient can be accessed by downloading the App or using your web browser.
Download our app today
Your Questions Answered
For your peace of mind, we can answer your questions quickly
What does NowPatient do?
NowPatient is an online pharmacy & telehealth service that is available in the US and UK. Our service is FREE and packed with useful features that can help you save money on the cost of your medications, access virtual treatments, and provide tools that can help improve your overall health.
Get started today and benefit from medication reminders, Get Treated Privately, NHS online pharmacy, GP appointment booking, Rx savings card, Drug Coupons, US drug savings programs, health conditions information, genetic testing, home test kits, BMI Risks, Type 2 Diabetes Risks, pollen meter, air quality monitor, and lots more!
Our service is operated by experienced medical professionals in the United States and the United Kingdom. You can view the online services that we provide by clicking Features.
UK users can safely and securely buy medicines online that treat a wide range of medical conditions. UK customers can also order NHS prescriptions online with the benefit of free tracked delivery.
US customers, regardless of insurance coverage, can enjoy huge savings on prescription medications using our various drug savings programs including drug coupons, savings card and manufacturer-sponsored patient assistance programs.
Where is NowPatient located?
NowPatient has offices in the United Kingdom and United States.
In the UK, we are located at:
NowPatient
28 Chipstead Valley Road
Coulsdon
Surrey
CR52RA
In the US, we are located at:
NowPatient
8911 North Capital of Texas Highway
Suite 4200 #1263
78759
Austin, TX
How can I contact NowPatient?
To contact NowPatient, please use the contact form available on the Contact Us page.
Alternatively, if you need to speak to us, you can reach us on the following numbers:
UK telephone number – 020 388 51 500
US telephone number – 1-866-967-1977
Who owns NowPatient?
NowPatient is owned and operated by Infohealth Ltd, a licensed online pharmacy with services spanning the UK, US and Rest of the World. Infohealth Ltd is registered in England and Wales under company number 04004930 and our registered office is at Lynwood House, 373 – 375 Station Road, Harrow, England, HA1 2AW.
Our website is www.nowpatient.com. Our App is called “NowPatient” and can be downloaded from the App Store (for Apple devices) or Google Play (for Android devices).
Can you tell me more about your NHS online pharmacy?
NowPatient’s Pharmaceutical services in the UK are provided by Infohealth Limited trading as ‘Infohealth Pharmacy’.
Our dispensing pharmacy is regulated and authorized for internet sales by the General Pharmaceutical Council (GPhC), registration number 1036487. You can view our license credentials on the General Pharmaceutical Council website. Our superintendent pharmacist who is responsible for the safe and effective oversight of medicines supplies is Mr Amish Patel (Registration Number 2042705).
Medicines are not ordinary items of commerce. All medicines or healthcare product sales are made under the supervision of a registered pharmacist who is licensed by the GPhC. At all times, we endeavour to provide a professional and transparent service whose primary goal is to ensure that the best interests of the patient are served.
How do I make a complaint?
From time to time, we accept that our service levels may not be up to your expectations. NowPatient welcomes concerns, compliments and complaints as valuable feedback that will help us learn from your experiences and make improvements. Feedback can be provided via our clear and transparent Complaints Procedures.
Can you tell me more about NowPatient’s prescribing services for treatments offered?
Our prescribing services are regulated by the General Pharmaceutical Council (GPhC). We provide the following regulated activity:
• treatment of disease, disorder, or injury
• transport services, triage, and medical advice are provided remotely
• caring for adults over 65 years old
• caring for adults under 65 years old
NowPatient prescribing services are run by Infohealth Limited. The Clinical Safety Officer and nominated individual is Mr Navin Khosla.
Can you tell me more about NowPatient’s US services?
Our head of US services is Dr. Jamie Winn.
You can lower the cost of your prescription medications using our various savings programs which include drug coupons, savings card and manufacturer-sponsored patient assistance programs.
We do not provide any prescribing services or dispensing services in the United States.
Is NowPatient legit and can I trust information from NowPatient?
Yes. NowPatient provides trustworthy and accessible clinical, health education and prescription services. We are also trusted by the NHS to deliver clinical and NHS repeat prescription dispensing across the whole of England. In the United States, we work with over 65,000 pharmacies to deliver considerable costs savings for our users.
NowPatient is operated by experienced licensed medical professionals in the United Kingdom and United States. Our Medical Team can be found here.
Our service is trusted by thousands of patients worldwide. You can read their reviews on our Trustpilot:
What are NowPatient’s opening hours?
Our office hours are:
UK – Monday-Friday 9am-6pm GMT
US – Monday-Friday 8am-5pm EST
Please note that we are closed at weekends.
In the event of a medical life-threatening emergency please call:
UK – 999
US – 911
In the event of a medical emergency which is not life-threatening please call:
UK – 111